The global bioproduction market is experiencing robust expansion, driven by the increasing demand for biologics, advancements in biotechnology, and the rising need for innovative therapeutic solutions. Bioproduction plays a critical role in the manufacturing of biological products such as vaccines, monoclonal antibodies, cell and gene therapies, and biosimilars, which are increasingly used to treat complex and chronic diseases.

According to market estimates, the bioproduction market size is projected to grow from US$ 22,337.24 million in 2022 to US$ 63,393.93 million by 2030, reflecting significant industry growth. The market is estimated to record a CAGR of 13.9% during 2022–2030, highlighting strong momentum driven by technological advancements and rising healthcare demand.

Market Drivers: Key Factors Fueling Bioproduction Market Growth

Rising Adoption of Biologics and Biosimilars

One of the primary drivers of the bioproduction market is the increasing demand for biologics and biosimilars. These therapies are widely used in the treatment of chronic diseases such as cancer, autoimmune disorders, and cardiovascular conditions. Biologics offer targeted treatment approaches, improving patient outcomes and driving large-scale production needs. Additionally, the expiration of patents for major biologics is encouraging the development of biosimilars, further boosting demand for bioproduction capabilities.

Get Sample PDF - https://www.theinsightpartners.com/sample/TIPRE00030322

Growing Prevalence of Chronic Diseases

The rising global burden of chronic diseases is significantly contributing to the expansion of the bioproduction market. Conditions such as cancer, diabetes, and cardiovascular disorders require advanced biologic therapies, increasing the need for efficient and scalable production processes. The growing patient population and demand for effective treatments are driving investments in biopharmaceutical manufacturing infrastructure.

Increasing Adoption of Regenerative Medicine and Cell Therapies

Regenerative medicine, including cell and gene therapies, is emerging as a major growth driver in the bioproduction market. These therapies aim to repair or replace damaged tissues and cells, offering promising solutions for previously untreatable diseases. The increasing number of clinical trials and commercialization of these therapies are driving demand for advanced bioproduction systems and technologies.

Technological Advancements and Automation in Manufacturing

Automation and digitalization are transforming bioproduction processes. Advanced manufacturing technologies such as automated bioreactors, closed-system processing, and digital workflow management are improving efficiency, reducing contamination risks, and lowering production costs. The transition from small-scale production to large-scale commercial manufacturing of cell therapies is further accelerating the adoption of automated solutions.

Expansion of Biopharmaceutical Companies and CROs

The increasing number of biopharmaceutical companies and contract manufacturing organizations (CMOs) is another key driver of market growth. These organizations are investing heavily in research and development to bring new biologic therapies to market. Collaborations, partnerships, and outsourcing of manufacturing processes are enabling faster drug development and scaling of production capacities globally.

Patent Expiry of Blockbuster Biologics

The expiration of patents for several high-revenue biologics is creating significant opportunities for biosimilar development. This trend is intensifying competition among market players and increasing the demand for cost-effective production solutions. As a result, bioproduction technologies are evolving to support efficient and scalable manufacturing of biosimilars.

Market Segmentation Insights

The bioproduction market is segmented based on product, application, equipment, and end user. By product, biologics and biosimilars dominate the market due to their widespread use in disease treatment. However, the cell and gene therapies segment is expected to register the highest growth rate, driven by increasing research and clinical adoption.

In terms of application, cancer remains a leading segment due to the high demand for biologic therapies in oncology. Based on equipment, consumables and accessories hold a significant share, as they are essential throughout the production and quality control processes. Biopharmaceutical companies represent the largest end-user segment, while contract manufacturing organizations are expected to witness rapid growth.

Top Players in the Global Bioproduction Market

• Lonza Group AG
• Danaher Corporation
• Sartorius AG
• Thermo Fisher Scientific Inc.
• Merck KGaA
• F. Hoffmann-La Roche Ltd
• Bio-Rad Laboratories Inc.
• FUJIFILM Irvine Scientific Inc.
• bbi-biotech GmbH
• GE Healthcare (Cytiva)

These companies are focusing on automation technologies, strategic collaborations, and expansion of manufacturing capabilities to meet the growing demand for biologics and advanced therapies.

Future Outlook: Bioproduction Market by 2030

The future of the bioproduction market is highly promising, supported by rapid advancements in biotechnology and increasing demand for personalized medicine. The industry is expected to witness significant transformation through the adoption of AI-driven manufacturing, continuous bioprocessing, and single-use technologies.

Emerging markets in Asia-Pacific are anticipated to offer substantial growth opportunities due to expanding healthcare infrastructure, increasing R&D investments, and supportive regulatory frameworks. Additionally, the growing focus on precision medicine and targeted therapies will further drive innovation in bioproduction processes.

Overall, the bioproduction market is set for strong double-digit growth, driven by the convergence of scientific innovation, rising disease burden, and increasing demand for efficient biologic manufacturing.

Frequently Asked Questions (FAQs)

1. What is the growth rate of the global bioproduction market?

The global bioproduction market is expected to grow at a CAGR of 13.9% from 2022 to 2030, driven by increasing demand for biologics and advancements in manufacturing technologies.

2. What is the projected market size of the bioproduction market by 2030?

The market is projected to reach US$ 63,393.93 million by 2030, up from US$ 22,337.24 million in 2022.

3. What are the key drivers of the bioproduction market?

Key drivers include rising adoption of biologics and biosimilars, increasing prevalence of chronic diseases, growth in regenerative medicine and cell therapies, technological advancements in manufacturing, and patent expiry of major biologics.

Top Trending Reports:

Cell Lysis Market Growth, Trends, and Forecast by 2031

3D Hydrogels for Cell Culture Market Statistics, Analysis, and Key Players by 2031

Gene Editing Market Growth, Trends, and Analysis by 2030

About Us

The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.

Contact Us

The Insight Partners
Email: sales@theinsightpartners.com
Phone: +1-646-491-9876
Website: www.theinsightpartners.com

Also Available in: Korean German Japanese French Chinese Italian Spanish